Oblenio Bio
Business Services · Massachusetts, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
4 Maguire Rd, Lexington, Massachusetts, ...Website
www.obleniobio.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Oblenio Bio
Oblenio Bio is a biotechnology company developing next-generation immunotherapies for severe autoimmune diseases. The company is advancing tri-specific T-cell engager therapies designed to selectively deplete disease-causing immune cells and achieve long-term immune reset. Its research focuses on addressing the underlying mechanisms of autoimmune disorders to develop transformative treatments with the potential for durable, drug-free remission.Explore more
Oblenio Bio Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Oblenio Bio your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Oblenio Bio
Product Launch: Get notified when Oblenio Bio launches new products
Earning: See what the market has to say on Oblenio Bio recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Oblenio Bio has new funding data
Check out if Oblenio Bio is spiking on competitors!
Oblenio Bio, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Click to see if Oblenio Bio had a recent Job posting/layoffs
Check if Oblenio Bio has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Find VP level buyers at Oblenio Bio
Find 3 more new buyers
Company Profile Activity
Activity Insights
Oblenio Bio is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Oblenio Bio is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Oblenio Bio.
Oblenio Bio financials insights
Gather financial insights about Oblenio Bio, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2026
Series B
$62M
Most Recent Scoops
Open Position
Open Position
Funding
Funding
Funding
Oblenio Bio News & Media
Oblenio Bio closes $62 million Series B led by Pfizer Ventures | The Pharmaletter
Cambridge, USA-based Oblenio Bio has announced the closing of an oversubscribed $62 million Series B financing round, positioning the company as an emerging leader in the treatment of autoimmune disease.
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Oblenio Bio
Sign Up For FreeTo access detailed company insights
Oblenio Bio is a biotechnology company developing next-generation immunotherapies for severe autoimmune diseases. The company is advancing tri-specific T-cell engager therapies designed to selectively deplete disease-causing immune cells and achieve long-term immune reset. Its research focuses on addressing the underlying mechanisms of autoimmune d... Read More
